HMG CoA reductase inhibitors
Browse ingredients, then choose a strength and product. Ontario inventory only; not a treatment recommendation.
ROSUVASTATIN CALCIUM: products 21 to 40 of 80.
Prices below are the ministry's recorded amounts per source unit, not pharmacy quotes or the patient's payment. Different strengths, forms and package units are not directly comparable. The cost plan asks for quantity and refill details.
| Product / strength / form | Ontario listing | Recorded ministry price | Next step |
|---|---|---|---|
| Jamp Rosuvastatin Calcium 10mg TabDIN 02498340 | General benefit | $0.1354per source unit | Requirements & sourcesBuild cost plan |
| Jamp Rosuvastatin Calcium 20mg TabDIN 02498359 | General benefit | $0.1692per source unit | Requirements & sourcesBuild cost plan |
| Jamp Rosuvastatin Calcium 40mg TabDIN 02498367 | General benefit | $0.1990per source unit | Requirements & sourcesBuild cost plan |
| Jamp Rosuvastatin Calcium 5mg TabDIN 02498332 | General benefit | $0.1284per source unit | Requirements & sourcesBuild cost plan |
| Jamp-Rosuvastatin 10mg TabDIN 02391260 | General benefit | $0.1354per source unit | Requirements & sourcesBuild cost plan |
| Jamp-Rosuvastatin 20mg TabDIN 02391279 | General benefit | $0.1692per source unit | Requirements & sourcesBuild cost plan |
| Jamp-Rosuvastatin 40mg TabDIN 02391287 | General benefit | $0.1990per source unit | Requirements & sourcesBuild cost plan |
| Jamp-Rosuvastatin 5mg TabDIN 02391252 | General benefit | $0.1284per source unit | Requirements & sourcesBuild cost plan |
| M-Rosuvastatin 10mg TabDIN 02496542 | General benefit | $0.1354per source unit | Requirements & sourcesBuild cost plan |
| M-Rosuvastatin 20mg TabDIN 02496550 | General benefit | $0.1692per source unit | Requirements & sourcesBuild cost plan |
| M-Rosuvastatin 40mg TabDIN 02496569 | General benefit | $0.1990per source unit | Requirements & sourcesBuild cost plan |
| M-Rosuvastatin 5mg TabDIN 02496534 | General benefit | $0.1284per source unit | Requirements & sourcesBuild cost plan |
| Mar-Rosuvastatin 10mg TabDIN 02413078 | General benefit | $0.1354per source unit | Requirements & sourcesBuild cost plan |
| Mar-Rosuvastatin 20mg TabDIN 02413086 | General benefit | $0.1692per source unit | Requirements & sourcesBuild cost plan |
| Mar-Rosuvastatin 40mg TabDIN 02413108 | General benefit | $0.1990per source unit | Requirements & sourcesBuild cost plan |
| Mar-Rosuvastatin 5mg TabDIN 02413051 | General benefit | $0.1284per source unit | Requirements & sourcesBuild cost plan |
| Med-Rosuvastatin 10mg TabDIN 02399172 | General benefit | $0.1354per source unit | Requirements & sourcesBuild cost plan |
| Med-Rosuvastatin 20mg TabDIN 02399180 | General benefit | $0.1692per source unit | Requirements & sourcesBuild cost plan |
| Med-Rosuvastatin 40mg TabDIN 02399199 | General benefit | $0.1990per source unit | Requirements & sourcesBuild cost plan |
| Med-Rosuvastatin 5mg TabDIN 02399164 | General benefit | $0.1284per source unit | Requirements & sourcesBuild cost plan |
Not seeing a product? Search Canadian records by medication name or DIN. Absence from this Ontario extract does not establish non-coverage. Open an exact product for its dated Health Canada status; a listing is not a stock check.
Class sources and program rules
Ontario Ministry of Health: odb-formulary-ed43-extract-2026-08-26.xml, extract 2026-08-26. Ontario class index: formulary-ed43-front-matter.txt, Part V.
Products assigned to this ATC category in the held Health Canada records. Combinations assigned to other categories are not included; search their ingredient or product name separately.
C10AA HMG CoA reductase inhibitors. Health Canada DPD extract 2026-09-02.
WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index, 2026-01-20
C10AA HMG CoA reductase inhibitors